Scott Lassman, JD, partner in Goodwin's Technology and Life Sciences Group, describes trends in state legislation on drug pricing and industry reaction to such laws.
Transcript:
Despite challenges from industry groups, a number of states have recently enacted drug pricing regulation. Do you expect to see more states passing such laws?
I think I just read that there were 2 more states that had either proposed or enacted similar legislation to what Maryland passed. This is an outgrowth of the whole concern about drug pricing, so I think it’s something that’s going to continue.
The pharmaceutical companies and the associations I think are going to continue to fight against those, and I think they’re going to do it for a number of reasons. One, a lot of the laws are somewhat vague and make it difficult to determine whether someone is violating the law or not.
The other big issue is, when you’ve got different requirements in different states it makes it very difficult for companies to price their products. I think there’s going to be a big push to try and get some sort of national standard.
We saw this many years ago with clinical trial disclosure requirements. A number of states started enacting laws requiring companies to disclose clinical trial information; I think Maine was the first one. Again, industry was very concerned about having multiple, disparate requirements from state to state, so they pushed for a national requirement, and that was enacted back in 2007. This is one of those issues that I think companies will want to have any national legislation, but I think they are going to fight against having different requirements in different states.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.